Quick Search:

uzh logo
Browse by:
bullet
bullet
bullet
bullet

Zurich Open Repository and Archive 

Hermann, M; Ruschitzka, F (2007). Cardiovascular risk of cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs. Annals of Medicine, 39(1):18-27.

Full text not available from this repository.

Abstract

Since selective cyclooxygenase-2 inhibitors (coxibs) entered the market, there has been concern about the cardiovascular safety of coxibs. In addition, recent data suggest that classical non-steroidal anti-inflammatory drugs (NSAIDs) have a similar cardiovascular risk. Importantly, all of the clinical trials with NSAIDs and coxibs so far were not purpose-designed to specifically and prospectively address cardiovascular safety and were clearly underpowered to detect any meaningful differences. In this current uncertainty about safety of NSAIDs and coxibs, the definitive answer as to the net effect of coxibs and NSAIDs on cardiovascular events can only be provided by well designed adequately powered, long-term clinical trials, which is now under way

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Cardiology
DDC:610 Medicine & health
Uncontrolled Keywords:Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use;Cardiovascular Diseases/*chemically induced;Clinical Trials as Topic;Cyclooxygenase 2 Inhibitors/*adverse effects/therapeutic use;Humans;Pain/*drug therapy;Prognosis;Risk Factors
Date:2007
Deposited On:04 Jan 2011 16:36
Last Modified:27 Nov 2013 19:28
Publisher:Informa Healthcare
ISSN:0785-3890
Free access at:PubMed ID. An embargo period may apply.
Publisher DOI:10.1080/07853890601073445
PubMed ID:17364448
Citations:Web of Science®. Times Cited: 20
Google Scholar™

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page